<DOC>
	<DOC>NCT00785928</DOC>
	<brief_summary>To assess the efficacy of LY2127399 versus placebo using ACR50 response scale at 24 weeks</brief_summary>
	<brief_title>A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Have given written informed consent Women must not be at risk to become pregnant during study participation Diagnosis of Rheumatoid Arthritis Current, regular use of Methotrexate, at a stable dose Other criteria to be reviewed by study doctor Use of excluded medications(reviewed by study doctor) Have not failed biologic TNFa inhibitor therapy Have had recent or ongoing infection which, in the opinion of the study doctor put patient at an unacceptable risk for participation in the study Evidence of tuberculosis Have systemic inflammatory condition other than RA, such as juvenile RA, Crohn's disease, ulcerative colitis, psoriatic arthritis or seronegative spondyloarthropathy Other criteria to be reviewed by study doctor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Arthritis</keyword>
</DOC>